Three cases of autoinflammatory disease with novel NLRC4 mutations, and the first mutation reported in the CARD domain of NLRC4 associated with autoinflammatory infantile enterocolitis (AIFEC).
AIFEC
Autoinflammatory infantile enterocolitis
FCAS4
Familial cold autoinflammatory syndrome
NLRC4
NLRC4-MAS
NLRC4-macrophage associated syndrome
Journal
Pediatric rheumatology online journal
ISSN: 1546-0096
Titre abrégé: Pediatr Rheumatol Online J
Pays: England
ID NLM: 101248897
Informations de publication
Date de publication:
18 Oct 2024
18 Oct 2024
Historique:
received:
03
06
2024
accepted:
26
08
2024
medline:
19
10
2024
pubmed:
19
10
2024
entrez:
18
10
2024
Statut:
epublish
Résumé
Gain of function (GOF) mutations in NOD-like receptor family CARD-containing 4 protein (NLRC4) gene induce a wide spectrum of autoinflammatory phenotypes. Currently, we categorize them into four groups: familial cold autoinflammatory syndrome (FCAS)4, autoinflammatory infantile enterocolitis (AIFEC), NLRC4-macrophage associated syndrome (MAS), and neonatal-onset multisystem inflammatory disease (NOMID). The rarity and complexity of the disease necessitate the description of new cases and a reexamination of our understanding of the condition. We present three patients with NLRC4-GOF mutations and AIFEC phenotypes. The first patient is an infant girl with periodic fever, seizure, high inflammatory markers, and an episode of macrophage associated syndrome (MAS). History of recurrent fever episodes since childhood was reported in mother and maternal grandmother. A heterozygous mutation was found in CARD domain of NLRC4: c.A91C: p.Asn31His. The second patient is an adolescent boy with periodic fever, diarrhea, aphthous stomatitis, seizure, and central nervous system (CNS) vasculitis. A heterozygous mutation was found in NLRC4 gene: c.1202T > C. p. Val401Ala. The third patient is a child with chronic diarrhea and elevated inflammatory markers. We found a heterozygous mutation in NLRC4 gene: c.390delG: p.S132Afs*21. All mutations have been reported for the first time as NLRC4 mutations associated with autoinflammation. We introduced novel mutations in the CARD domain and between CARD and NBD domain in the first and third cases, respectively. All three children are under remission following treatment. NLRC4-GOF mutations can be associated with autoinflammation with diverse symptoms. Given the rarity of the disease and the possibility of new mutations being identified, the existence of a phenotype/genotype correlation has yet to be thoroughly investigated. The variety in manifestations and severity spectrum mandates a variety of treatments. Adalimumab has shown favorable outcomes in our AIFEC cases.
Sections du résumé
BACKGROUND
BACKGROUND
Gain of function (GOF) mutations in NOD-like receptor family CARD-containing 4 protein (NLRC4) gene induce a wide spectrum of autoinflammatory phenotypes. Currently, we categorize them into four groups: familial cold autoinflammatory syndrome (FCAS)4, autoinflammatory infantile enterocolitis (AIFEC), NLRC4-macrophage associated syndrome (MAS), and neonatal-onset multisystem inflammatory disease (NOMID). The rarity and complexity of the disease necessitate the description of new cases and a reexamination of our understanding of the condition.
CASE PRESENTATIONS
METHODS
We present three patients with NLRC4-GOF mutations and AIFEC phenotypes. The first patient is an infant girl with periodic fever, seizure, high inflammatory markers, and an episode of macrophage associated syndrome (MAS). History of recurrent fever episodes since childhood was reported in mother and maternal grandmother. A heterozygous mutation was found in CARD domain of NLRC4: c.A91C: p.Asn31His. The second patient is an adolescent boy with periodic fever, diarrhea, aphthous stomatitis, seizure, and central nervous system (CNS) vasculitis. A heterozygous mutation was found in NLRC4 gene: c.1202T > C. p. Val401Ala. The third patient is a child with chronic diarrhea and elevated inflammatory markers. We found a heterozygous mutation in NLRC4 gene: c.390delG: p.S132Afs*21. All mutations have been reported for the first time as NLRC4 mutations associated with autoinflammation. We introduced novel mutations in the CARD domain and between CARD and NBD domain in the first and third cases, respectively. All three children are under remission following treatment.
CONCLUSIONS
CONCLUSIONS
NLRC4-GOF mutations can be associated with autoinflammation with diverse symptoms. Given the rarity of the disease and the possibility of new mutations being identified, the existence of a phenotype/genotype correlation has yet to be thoroughly investigated. The variety in manifestations and severity spectrum mandates a variety of treatments. Adalimumab has shown favorable outcomes in our AIFEC cases.
Identifiants
pubmed: 39425177
doi: 10.1186/s12969-024-01020-z
pii: 10.1186/s12969-024-01020-z
doi:
Substances chimiques
NLRC4 protein, human
0
CARD Signaling Adaptor Proteins
0
Calcium-Binding Proteins
0
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
90Informations de copyright
© 2024. The Author(s).
Références
de Zoete MR, Palm NW, Zhu S, Flavell RA, Inflammasomes. Cold Spring Harb Perspect Biol. 2014;6(12):a016287.
doi: 10.1101/cshperspect.a016287
pubmed: 25324215
pmcid: 4292152
Guo H, Callaway JB, Ting JP. Inflammasomes: mechanism of action, role in disease, and therapeutics. Nat Med. 2015;21(7):677–87.
doi: 10.1038/nm.3893
pubmed: 26121197
pmcid: 4519035
Hu Z, Yan C, Liu P, Huang Z, Ma R, Zhang C, et al. Crystal structure of NLRC4 reveals its autoinhibition mechanism. Science. 2013;341(6142):172–5.
doi: 10.1126/science.1236381
pubmed: 23765277
Wen J, Xuan B, Liu Y, Wang L, He L, Meng X, et al. Updating the NLRC4 inflammasome: from bacterial infections to autoimmunity and cancer. Front Immunol. 2021;12:702527.
doi: 10.3389/fimmu.2021.702527
pubmed: 34276697
pmcid: 8283967
Wang L, Wen W, Deng M, Li Y, Sun G, Zhao X, et al. A novel mutation in the NBD domain of NLRC4 causes mild autoinflammation with recurrent urticaria. Front Immunol. 2021;12:674808.
doi: 10.3389/fimmu.2021.674808
pubmed: 34248956
pmcid: 8260849
Moghaddas F, Zeng P, Zhang Y, Schützle H, Brenner S, Hofmann SR, et al. Autoinflammatory mutation in NLRC4 reveals a leucine-rich repeat (LRR)–LRR oligomerization interface. J Allergy Clin Immunol. 2018;142(6):1956–67. e6.
doi: 10.1016/j.jaci.2018.04.033
pubmed: 29778503
pmcid: 6281029
Canna SW, Girard C, Malle L, de Jesus A, Romberg N, Kelsen J, et al. Life-threatening NLRC4-associated hyperinflammation successfully treated with IL-18 inhibition. J Allergy Clin Immunol. 2017;139(5):1698–701.
doi: 10.1016/j.jaci.2016.10.022
pubmed: 27876626
Romberg N, Al Moussawi K, Nelson-Williams C, Stiegler AL, Loring E, Choi M, et al. Mutation of NLRC4 causes a syndrome of enterocolitis and autoinflammation. Nat Genet. 2014;46(10):1135–9.
doi: 10.1038/ng.3066
pubmed: 25217960
pmcid: 4177367
Volker-Touw C, De Koning H, Giltay J, De Kovel CG, Van Kempen T, Oberndorff K, et al. Erythematous nodes, urticarial rash and arthralgias in a large pedigree with NLRC4‐related autoinflammatory disease, expansion of the phenotype. Br J Dermatol. 2017;176(1):244–8.
doi: 10.1111/bjd.14757
pubmed: 27203668
Kawasaki Y, Oda H, Ito J, Niwa A, Tanaka T, Hijikata A, et al. Identification of a high-frequency somatic NLRC4 mutation as a cause of autoinflammation by pluripotent cell–based phenotype dissection. Arthritis Rheumatol. 2017;69(2):447–59.
doi: 10.1002/art.39960
pubmed: 27788288
Bardet J, Laverdure N, Fusaro M, Picard C, Garnier L, Viel S, et al. NLRC4 GOF mutations, a challenging diagnosis from neonatal age to adulthood. J Clin Med. 2021;10(19):4369.
doi: 10.3390/jcm10194369
pubmed: 34640385
pmcid: 8509521
Romberg N, Vogel TP, Canna SW. NLRC4 inflammasomopathies. Curr Opin Allergy Clin Immunol. 2017;17(6):398–404.
doi: 10.1097/ACI.0000000000000396
pubmed: 28957823
pmcid: 6070355
Canna SW, de Jesus AA, Gouni S, Brooks SR, Marrero B, Liu Y, et al. An activating NLRC4 inflammasome mutation causes autoinflammation with recurrent macrophage activation syndrome. Nat Genet. 2014;46(10):1140–6.
doi: 10.1038/ng.3089
pubmed: 25217959
pmcid: 4177369
Wang Q, Ye X, Zheng W, Jin T, Zhou Y, Hu X, et al. NLRC4 gain-of-function variant is identified in a patient with systemic lupus erythematosus. Clin Immunol. 2023;255:109731.
doi: 10.1016/j.clim.2023.109731
pubmed: 37567492
Ionescu D, Peñín-Franch A, Mensa-Vilaró A, Castillo P, Hurtado-Navarro L, Molina-López C, et al. First description of late-onset Autoinflammatory Disease due to somatic NLRC4 mosaicism. Arthritis Rheumatol. 2022;74(4):692–9.
doi: 10.1002/art.41999
pubmed: 34672126
Wang J, Ye Q, Zheng W, Yu X, Luo F, Fang R, et al. Low-ratio somatic NLRC4 mutation causes late-onset autoinflammatory disease. Ann Rheum Dis. 2022;81(8):1173–8.
doi: 10.1136/annrheumdis-2021-221708
pubmed: 35428651
Jeskey J, Parida A, Graven K, Hostoffer R. Novel gene deletion in NLRC4 expanding the familial cold inflammatory syndrome phenotype. Allergy Rhinology. 2020;11:2152656720928062.
doi: 10.1177/2152656720928062
pubmed: 32537258
pmcid: 7268108
Bracaglia C, Gatto A, Pardeo M, Lapeyre G, Ferlin W, Nelson R, et al. Anti interferon-gamma (IFNγ) monoclonal antibody treatment in a patient carrying an NLRC4 mutation and severe hemophagocytic lymphohistiocytosis. Pediatr Rheumatol. 2015;13(1):1–2.
A Three-period Multicenter Study, With a Randomized-withdrawal, Double-blind, Placebo-controlled Design to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Patients With Monogenic IL-18 Driven Autoinflammatory Diseases, Including NLRC4-GOF, XIAP Deficiency, or CDC42 Mutations [Internet]. 2020. https://clinicaltrials.gov/study/NCT04641442
Bracaglia C, Marucci G, Del Chierico F, Russo A, Pardeo M, Pires Marafon D, et al. Microbiota transplant to control inflammation in a patient with NLRC4 gain-of-function-induced disease. J Allergy Clin Immunol. 2023;152(1):302–3.
doi: 10.1016/j.jaci.2023.03.031
pubmed: 37178069